Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naive patients with HBeAg positive chronic hepatitis B Sulkowski, M. S., Fung, S. K., Ma, X., Nguyen, T. T., Schiff, E. R., Hann, H. L., Dieterich, D. T., Nahass, R. G., Park, J. S., Chan, S., Han, S. B., Gane, E. J., Bennett, M., Yan, R., Liu, J., Ma, J., Knox, S. J., Stamm, L. M., Bonacini, M., Jacobson, I. M., Ayoub, W. S., Weilert, F., Ravendhran, N., Ramji, A., Kwo, P., Elkhashab, M., Hassanein, T., Bae, H. S., Lalezari, J. P., Agarwal, K., Yuen, M. ELSEVIER. 2022: S836-S837
View details for Web of Science ID 000826275104210